戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                Data from 5,171 patients were assessable.
2 tal of 30 patients were enrolled and 28 were assessable.
3                 Three patients (6%) were not assessable.
4 rty-nine patients (25 with M1c disease) were assessable.
5                 A total of 644 patients were assessable.
6  195; BCT, n = 200) were deemed eligible and assessable.
7 atients; thus, 140 patients in each arm were assessable.
8         One died within 72 hours and was not assessable.
9            219 of 227 enrolled patients were assessable.
10     There were 26 patients enrolled; 18 were assessable.
11 ts were enrolled onto the study, and 53 were assessable.
12 3) had at least 1 subcompetency rated as not assessable.
13      219 of these 227 enrolled patients were assessable.
14 1,551 randomly assigned patients, 1,524 were assessable.
15 ons; of those, 54 patients were eligible and assessable.
16 ach specific cytogenetic abnormality was not assessable.
17 Forty-nine patients were entered and 43 were assessable (12% stage IB; 37% stage II; and 52% stage II
18 tients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine treatme
19                 A total of 651 patients were assessable (227 randomly assigned to tamoxifen and 424 r
20  Of 682 patients enrolled, 644 patients were assessable and analyzed.
21 nts had no PSA response and 6 (15%) were not assessable and assumed to be nonresponders.
22                                   Tissue was assessable and ER and/or PgR positivity confirmed centra
23 ntle cell lymphoma were enrolled and 69 were assessable and were included in the final analysis.
24  and 7, at least 12 patients per cohort were assessable, and the dose level with prospectively define
25  100% histologic cure was achieved in 9 of 9 assessable animals without detectable radiation damage t
26                          More than 90% of 26 assessable archival tumor specimens were highly positive
27  (arm A, n = 41; arm B, n = 43), and 72 were assessable (arm A, n = 37; arm B, n = 35).
28  of patients assigned erlotinib and who were assessable at 1 month developed first-cycle rash, which
29 d 132 (31%) patients, respectively, were not assessable at 2 months and were counted as missing data
30 F and survival were compared in 135 patients assessable at 2 months with tumor shrinkage below (poor
31            One hundred sixteen patients were assessable at 3 months postoperatively.
32 and Human Development to relate risk factors assessable at or before birth to the likelihood of survi
33 one individual with thymic carcinoma was not assessable because she died.
34 ted ascending aortic geometries that are not assessable by current echocardiographic measures.
35 ed C1 and C2, respectively) and were MFC-MRD assessable by LAIP detection in CR bone marrow for at le
36                             Of nine patients assessable by PET,responses were complete in five patien
37 acteristics and patient-related risk factors assessable by the clinician at patient presentation can
38 ic modifications of mucus contrasts that are assessable by using a noninvasive, contrast material-fre
39           Of the 26 measures, 10 are readily assessable by using cancer registry data.
40 ee hundred eighty-five patients patients had assessable CA 19-9 levels.
41                                 Of 910 total assessable cases, 112 of 488 ErbB-2-positive cases (23%)
42       Effusions were exudative in 78% of the assessable cases.
43 xclusively based on objective preoperatively assessable characteristics and can be rapidly and easily
44                                   Of 294/315 assessable children, 15/294 had pure spasticity, leaving
45 ry tumour samples, of whom 865 (50%) had two assessable cores (445 in the control groups and 420 in t
46  seen in 51 of 73 patients and in 107 of 209 assessable coronary arteries.
47                            The percentage of assessable coronary artery segments was 98.6% (1196 of 1
48 er D-serine (n=20) or placebo (n=24); 35 had assessable data (15 D-serine, 20 placebo).
49 ble patients were enrolled, of whom 1941 had assessable data (968 in the capecitabine alone group and
50 y and either gefitinib or erlotinib, and had assessable disease (RECIST 1.1) and tumour tissue sample
51                      Ten of 46 patients with assessable disease had a partial response, and these res
52 ne included FOLFOX4 treatment, patients with assessable disease, or a single site of metastasis.
53 y Group performance status of 2 or less; had assessable disease; were not suitable to receive any est
54 CU days of observation in which delirium was assessable (e.g., patient was noncomatose), with a total
55 NSCLC), and that this determination might be assessable early on during therapy.
56           The proportions of patients having assessable EORTC QLQ-C30 and EQ-5D questionnaires at bas
57  published primary outcome with 90% of those assessable favoring a statistically positive result.
58                            Among 33 patients assessable for a cytogenetic response, 17 (52%) experien
59 led and given cabozantinib; 25 patients were assessable for a response.
60                    All treated patients were assessable for a response.
61 prised the full analysis set and were deemed assessable for activity.
62 ylphenidate and 53 in the placebo group were assessable for analysis.
63                             50 patients were assessable for both toxic effects and response; eight ad
64 erapy for at least 1 year, 173 patients were assessable for cardiac toxicity.
65                             30 patients were assessable for change in lean body mass, which increased
66                  Of the 12 patients who were assessable for chemotherapeutic response (pre-RT), the o
67 Of 104 patients recruited, 100 patients were assessable for clinical benefit prior to planned nephrec
68                One hundred ten patients were assessable for clinical efficacy.
69             Of 42 patients enrolled, 39 were assessable for clinical outcome and DC analysis.
70                               Of 43 patients assessable for clinical response, two patients had confi
71                            Among 73 patients assessable for clonal evolution during stable chronic ph
72  ten in the safety expansion group); 31 were assessable for efficacy (<400 mg, n=16; 400 mg, n=15).
73                 A total of 133 patients were assessable for efficacy and safety.
74                            All patients were assessable for efficacy and safety.
75                       Sixteen of 23 patients assessable for efficacy in the nonrandomized single-arm
76 in cohort 1 and 62 patients in cohort 2 were assessable for efficacy.
77  patients were enrolled and 30 patients were assessable for efficacy.
78 pezil group and 56 in the placebo group were assessable for final analysis.
79 to treatment in the CLARITY study, 1192 were assessable for freedom from disease activity at 96 weeks
80 f treatment received but restricted to those assessable for hearing loss.
81 hs of radiographic follow-up were considered assessable for local control.
82             Forty-nine discrete lesions were assessable for local control.
83                           Fifty lesions were assessable for local control.
84 enty-one patients were included, and 19 were assessable for metabolic response evaluation with FLT-PE
85 gy Study 9047 (1990-2000), 560 children were assessable for ploidy and MYCN amplification.
86                         Forty-seven patients assessable for PN received a median of five cycles of th
87 ved 400 mg, and 33 who received 1400 mg were assessable for PSA response at 12 weeks.
88                   However, among 40 patients assessable for radiologic response, none experienced par
89 242 patients enrolled, 224 were eligible and assessable for response (106 and 118 patients in the con
90                          Four of 18 patients assessable for response (22%; 95% CI, 2% to 42%) achieve
91           Forty-three enrolled patients were assessable for response and safety.
92             Seven of 30 registrants who were assessable for response had a partial response, and six
93 34/216) and 8% (18/214) of patients who were assessable for response in these respective groups had a
94                     Twenty-two patients were assessable for response, including 14 complete responses
95 Of 19 patients treated for refractory NB and assessable for response, nine showed evidence of disease
96                              Of 161 patients assessable for response, one patient with hepatoblastoma
97                        Among the 49 patients assessable for response, the objective response rate was
98 ents assessable for toxicity and 20 patients assessable for response.
99                         Thirty patients were assessable for response.
100 ) had progressive disease, and five were not assessable for response.
101 nsformed (20%) disease were treated; 74 were assessable for response.
102 al of 126 patients were treated and 113 were assessable for response.
103 were enrolled; 27 were eligible, and 26 were assessable for response.
104 ctory myeloma were enrolled, 34 of whom were assessable for response.
105 tients were entered onto the study, with 103 assessable for response.
106 female) were entered onto the trial and were assessable for response.
107                         All 17 patients were assessable for response.
108                      Sixty-six patients were assessable for response.
109                           Of the 47 patients assessable for safety, grade 3 or 4 hematologic events w
110 atients, 48 underwent two MRIs; 44 MRIs were assessable for study end points.
111              Four hundred four patients were assessable for surgical outcomes.
112  Forty-eight patients were entered; all were assessable for survival, and 47 were assessable for toxi
113              Of these, 104 participants were assessable for the primary endpoint (sodium thiosulfate,
114                        We deemed patients as assessable for the primary endpoint in the phase 1 porti
115                  175 (79%) participants were assessable for the primary outcome in the mITT populatio
116                Forty-two of 44 patients were assessable for this analysis.
117                 A total of 230 patients were assessable for this analysis: 99 patients with severe la
118 -non-amplified disease; 55 patients were not assessable for TOP2A status.
119  Dec 31, 2015, 23 patients were enrolled and assessable for toxic effects after completing accrual.
120 the study at levels 1 to 4, with 18 patients assessable for toxicity and 20 patients assessable for r
121 toma and no prior ASCT were entered; 22 were assessable for toxicity and response.
122 ll were assessable for survival, and 47 were assessable for toxicity and response.
123 icity) or 260 mg/m2/d (seven enrolled, three assessable for toxicity) of temozolomide.
124 ved either 200 mg/m2/d (nine enrolled, three assessable for toxicity) or 260 mg/m2/d (seven enrolled,
125                   Fifteen patients (12 fully assessable for toxicity) with first or later CD22-positi
126  21 years), were enrolled, and 42 were fully assessable for toxicity.
127 , and 18 completed one course and were fully assessable for toxicity.
128 ere enrolled, and 18 (12 with sarcomas) were assessable for toxicity.
129      Twenty-three patients were enrolled and assessable for toxicity.
130 years), were enrolled, of whom 29 were fully assessable for toxicity.
131 y-three solid tumor and 17 NF1 patients were assessable for toxicity.
132 one patients were enrolled; 32 patients were assessable for toxicity.
133  Thirty patients received treatment and were assessable for toxicity.
134  Thirty-five patients were enrolled and were assessable for toxicity; one patient had MCL by histolog
135                       Five patients were not assessable for tumor response.
136                             48 patients were assessable for tumour response.
137 patients for whom treatment and outcome were assessable had full (three patients) or partial (nine pa
138 -modality, and boost therapy, 37 (82%) of 45 assessable high-risk patients achieved a complete respon
139 the surgical ICU; 227 of 415 (55%) long-stay assessable ICU patients were weak; 122 weak patients wer
140                                Patients were assessable if eligible for the MA.27 trial, received som
141 ive analysis of 372 breast cancer cases with assessable immunohistochemical data for ER, PR, and Her-
142                   The combined end point was assessable in 155 (97%) patients.
143 y to SEE for functional recovery but was not assessable in 25% of patients.
144           Treatment effects and outcome were assessable in 501 (median follow-up 24 months, range 4-1
145                                EGFR FISH was assessable in 76 patients with available tumor tissue an
146                                EGFR FISH was assessable in 976 patients and 400 patients (41%) were E
147 logic conditions but has not been previously assessable in population cohorts.
148 6%) in the CBT group, whereas 135 (61%) were assessable in the PP population in the BA group compared
149                             A rating of "not assessable" indicated insufficient information to evalua
150                         Median follow-up for assessable lesions was 15.4 months (range, 6 to 48 month
151                         Median follow-up for assessable lesions was 16 months (range, 6 to 54 months)
152 acy analysis population (patients with fully assessable locally advanced disease and all those with m
153                                       All 15 assessable margins were clear on CLI and histopathology.
154            To identify a powerful and easily assessable miRNA bio-marker of prognosis and survival, w
155  patients where radial margin status was not assessable (n = 16).
156 ressive disease (PD), and seven patients not assessable (NA).
157 ble disease (SD) for 8 or more courses in 30 assessable neuroblastoma patients.
158  the new sensor array was tested for an easy assessable objective: coffee ageing during storage.
159 neteen of 122 randomly assigned patients had assessable outcomes.
160                  A total of 136 eligible and assessable patients (101 untreated, 35 previously treate
161 ith GBM (95% CI, 0.1% to 15%) and five of 32 assessable patients (16%) with anaplastic glioma (95% CI
162 73.9) in the capecitabine group and 18 of 35 assessable patients (51.4%, 39.4-63.4) in the gemcitabin
163                             There were 1,059 assessable patients (526 erlotinib; 533 placebo).
164                     After 9 months, 22 of 35 assessable patients (62.9%, 80% CI 50.6-73.9) in the cap
165                                  Four of six assessable patients (67%) with DLBCL achieved an OR, inc
166       Responses were observed in five of six assessable patients (83%) at the MTD.
167                          Fifteen (25%) of 59 assessable patients (95% CI, 16% to 37%) had objective r
168 urable responses were seen in 19 (76%) of 25 assessable patients (95% exact binomial CI, 55% to 91%),
169                   Between 1987 and 1991, 456 assessable patients (median age, 70 years) were enrolled
170 ot complete the cognitive screen, leaving 85 assessable patients (median age, 72 years).
171                                        Of 13 assessable patients (nine with adult T-cell leukaemia-ly
172 rtial responses seen in seven of 25 response-assessable patients (overall response 28%, 95% CI 12-49)
173                     Twenty-three (49%) of 47 assessable patients achieved a complete response (CR) to
174                               Two (8%) of 26 assessable patients achieved a partial response.
175                           Twelve (19%) of 62 assessable patients achieved an objective confirmed resp
176               In untreated AML, four of nine assessable patients achieved CR.
177                                  Three of 13 assessable patients achieved objective radiographic and/
178     Pseudoprogression was observed in 37% of assessable patients and may have had an impact on estima
179          In phase II, 8 (10%) of 84 response-assessable patients attained objective antitumor respons
180                                          All assessable patients engrafted, with median time for neut
181 d five partial responses were achieved in 35 assessable patients for an overall response rate of 17.1
182                               11 (18%) of 60 assessable patients had a confirmed objective response,
183  or 0.4 mg/kg every 6 weeks), 11 (18%) of 60 assessable patients had a confirmed objective response.
184 te toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity.
185                                    Six of 22 assessable patients had complete or partial response, an
186                             Nine (20%) of 46 assessable patients had confirmed partial responses unti
187 sistant neuroblastoma, and seven (50%) of 14 assessable patients had response or disease stabilizatio
188 sponses were needed in the first 20 response-assessable patients in each of the five tumour cohorts.
189 red orally daily to groups of at least three assessable patients in escalating doses of 50, 75, 100,
190          An interim analysis of the first 23 assessable patients in the first cohort treated at 420 m
191                               31 (76%) of 41 assessable patients in the fluorouracil group had grade
192                               34 (85%) of 40 assessable patients in the paclitaxel group had grade 3-
193                           Responses among 35 assessable patients included 10 partial responses (28.6%
194                        Prognostic factors in assessable patients included advanced stage (III/IV) in
195                                  Ninety-nine assessable patients received 6 cycles of doxorubicin 25
196                                     Fourteen assessable patients received 75 courses.
197                                   Fifty-four assessable patients received paclitaxel consolidation.
198                                   Forty-five assessable patients received protocol therapy.
199                             Treatment of six assessable patients resulted in one venous thrombosis; t
200 d 10.6 +/- 4.4 months, with nine of 16 (56%) assessable patients surviving 1 year or longer.
201                                 Twenty-three assessable patients taking EIAEDs received tipifarnib in
202                                  For the 146 assessable patients treated with bexarotene, median age
203 edian follow-up time, the overall RR for 121 assessable patients was 16.5% (95% CI, 10% to 26%); the
204 dian age at the time of follow-up for the 20 assessable patients was 16.9 years (IQR 15.5-21.8).
205           The 5-year survival rate of the 76 assessable patients was 24% (median, 20 months).
206                         The pCR rate for all assessable patients was 26% in each arm.
207                         Response rate in 141 assessable patients was 33% including 8% complete respon
208 an follow-up time for all 1,236 eligible and assessable patients was 35.7 months.
209        The overall response rate for the 130 assessable patients was 39% (chemotherapy, 34%; chemoimm
210                          The distribution of assessable patients was: two of three in cohort 1, three
211 he response rate and disease control rate in assessable patients were 36% and 82%, respectively.
212 he response rate and disease control rate in assessable patients were 36% and 82%, respectively.
213 ion (CR2) rates at the end of block 1 in 117 assessable patients were 68% +/- 6% for ER (n = 63) and
214                         Six hundred nineteen assessable patients were analyzed.
215                   A total of 553 consecutive assessable patients were enrolled onto a treatment proto
216 5% confirmed overall response rate (ORR), 41 assessable patients were needed.
217                                A total of 76 assessable patients were treated on this phase II trial,
218                                    Seventeen assessable patients were treated.
219                                   Of the six assessable patients who had declined the procedure, one
220                                    Of the 14 assessable patients who had successfully undergone ovari
221 tients who received 8 Gy vs 229 [66%] of 349 assessable patients who received 20 Gy; p=0.011) and dia
222                                   Two of six assessable patients who received 56 mg/m(2) had reversib
223 days were lack of appetite (201 [56%] of 358 assessable patients who received 8 Gy vs 229 [66%] of 34
224                               There were 303 assessable patients with a median follow-up of 68.4 mont
225                                        Of 11 assessable patients with AHWT, two had PR, one had SD, a
226  (arm A) or without oblimersen (arm B) in 56 assessable patients with chemotherapy-naive ES-SCLC.
227                                        Of 25 assessable patients with FHWT, 12 had partial response (
228  Between June 7, 2000, and Oct 24, 2007, 498 assessable patients with newly diagnosed ALL were enroll
229              Results One hundred eighty-five assessable patients with one of 10 subtypes of sarcoma w
230                             A total of 1,003 assessable patients with SLN metastasis had immediate (n
231 EFS) and overall survival (OS) estimates for assessable patients with stage I AH (n = 29) were 69.5%
232 ND METHODS Four hundred twenty-two eligible, assessable patients with stage IIIA/B NSCLC were treated
233                                        Of 23 assessable patients with thymic carcinoma, six (26%, 90%
234                                   Thirty-one assessable patients with uveal melanoma demonstrated two
235               Five studies (comprising 1,716 assessable patients) compared a 5-HT(3) antagonist with
236  [CR] and 13 partial responses [PR] among 44 assessable patients).
237                                       For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had
238                                        Of 21 assessable patients, 11 (52%) responded: four with morph
239                                    Of the 23 assessable patients, 16 had stable disease as their best
240                                        In 68 assessable patients, 17 (25%) had grade 3 to 4 esophagit
241                                       Of 396 assessable patients, 202 were randomly allocated to rece
242                                        Of 29 assessable patients, 22 were available for PK-based main
243                                        Of 83 assessable patients, 46 (55%, 95% CI 44-66) achieved a s
244                                    Of the 56 assessable patients, 48 underwent two MRIs; 44 MRIs were
245                                    Of the 76 assessable patients, 74 patients (97%) suffered grade 3
246                                        Of 97 assessable patients, 97% responded, and 87% achieved a c
247  Focusing on the 61 late-stage (IIIB and IV) assessable patients, a 15% partial response rate was ach
248                               Among response-assessable patients, an objective response was noted in
249                                        Of 16 assessable patients, best tumor responses observed were
250                               Of 30 efficacy-assessable patients, five had stable disease (SD) for at
251       The study consisted of 62 eligible and assessable patients, median age 57 years, 41 (66.1%) hav
252                                       For 42 assessable patients, median plasma interleukin-6 concent
253                                        Among assessable patients, response rate was 26.0% in cohort 1
254                                     Among 72 assessable patients, response rates of 65% and 50% were
255                       In six (27%) of the 22 assessable patients, the asymptomatic BM responded to sy
256                                          For assessable patients, the objective response rate (ORR) w
257       In the initially planned cohort of 100 assessable patients, the objective RR was 4% (95% CI, 1.
258                                        Of 48 assessable patients, the overall response rate was 31% (
259 achieved in seven (26% [95% CI 11-46]) of 27 assessable patients, with three (11% [2-29]) complete an
260 ifestations was observed in 26 (60.5%) of 43 assessable patients.
261 academic practices consecutively enrolled 89 assessable patients.
262 s (69%) and 23 partial responses (26%) in 90 assessable patients.
263  4 to 22+ months) was seen in 22 (59%) of 37 assessable patients.
264 r dose cohort (3,120 mg) was expanded to six assessable patients.
265 redetermined recruitment stages of 20 and 40 assessable patients.
266 s 11.5% (95% CI, 6.3% to 18.9%) for response-assessable patients.
267 mor cells was detected in 29 (81%) of the 36 assessable patients.
268 bjective response rate (RR) in the first 100 assessable patients.
269                There were no responses in 41 assessable patients.
270 a Evaluation in Solid Tumors version 1.1) in assessable patients; those who received at least one dos
271                         Approximately 70% of assessable peptide bond hydrogens were protected from ex
272                                              Assessable phenotypes before any antiviral treatment inc
273  In Solid Tumors version 1.1 in the response-assessable population (ie, patients with measurable dise
274 ecific antiviral therapy in the per-protocol assessable population.
275  the remaining 379 patients had incompletely assessable postoperative studies.
276 t severity, provides an objective and easily assessable predictive parameter.
277 entrations <50 nmol/L consisted of 13 easily assessable predictors, whereas the model for concentrati
278                         In 14 (78%) of 18 Tg-assessable PTC patients, Tg declined more than 25%.
279 cians surveyed, 535 (54%) and 378 (62%) were assessable, respectively.
280                              Analysis of 526 assessable respondents showed a wide variation in manage
281                           Moreover, 10 of 11 assessable responders who started therapy with reticulin
282 t reveal activating mutations in tumors from assessable responding patients.
283       Early responders (67% of patients with assessable response) achieved pCR in 35.7% compared with
284 er by fluorescent in situ hybridization (374 assessable samples), EGFR protein expression by immunohi
285  vaccine and who provided at least one valid assessable serum sample.
286                              In the response-assessable study population (n = 47), which had a median
287 ne resistance was present in 58 (53%) of 113 assessable study sites, spread across most countries tha
288  study vaccination and provided at least one assessable swab after baseline.
289                        Six patients were not assessable: three discontinued study drug because of a n
290 ipheral-blood mononuclear cells at the first assessable time point of G3139 exposure, and in eight of
291 F or RAS mutations were detected in 10 of 26 assessable tumor samples.
292                      VEGF-A levels in the 17 assessable tumors were higher than in normal breast tiss
293                          Ninety (60%) of 149 assessable tumors were KRAS or BRAF wild type (CAPOX, n
294              46 of 48 enrolled patients were assessable (two patients had unconfirmed diagnoses).
295  that included only objective preoperatively assessable variables was developed using a multivariate
296             Eight independent preoperatively assessable variables were identified and included in the
297      There were 24 patients, and 18 who were assessable were enrolled.
298              Twenty-nine of 31 patients were assessable with a variety of histologic subtypes.
299                Pain and sedation were always assessable with excellent inter-rater reliability (numer
300                    Thirty-three patients (31 assessable) with a median age of 12 years were enrolled.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top